This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Servier has granted Novartis an exclusive license to develop and market agomelatine in the US and several other countries. The MT1 and MT2 receptor agonist with 5-HT2c antagonist properties is in Phase III trials for major depressive disorder.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?